ABRAXANE® PLUS GEMCITABINE DEMONSTRATES SURVIVAL ADVANTAGE IN PHASE III STUDY OF PATIENTS WITH ADVANCED PANCREATIC CANCER Abraxane plus gemcitabine was superior to gemcitabine alone with statistically significant and cl - Protein-bound paclitaxel - Document - PDFSEARCH.IO

First Page	Meta Content
	ABRAXANE® PLUS GEMCITABINE DEMONSTRATES SURVIVAL ADVANTAGE IN PHASE III STUDY OF PATIENTS WITH ADVANCED PANCREATIC CANCER Abraxane plus gemcitabine was superior to gemcitabine alone with statistically significant and cl Add to Reading List Document Date: 2013-02-05 05:27:34 Open Document File Size: 54,04 KB Share Result on Facebook City San Francisco / / Company Celgene Corporation / / MedicalCondition metastatic pancreatic cancer / / Organization American Society / / Person Virginia G. Piper / Jean-Pierre Bizzari / Daniel D. Von Hoff / Hematology / / Position investigator / Executive Vice President / Officer / forward / / Product paclitaxel / ABRAXANE / / ProvinceOrState California / / SocialTag Benzamides Breast cancer Bristol-Myers Squibb Eli Lilly and Company Gemcitabine Organofluorides Pancreatic cancer End point of clinical trials Protein-bound paclitaxel Chemistry

ABRAXANE® PLUS GEMCITABINE DEMONSTRATES SURVIVAL ADVANTAGE IN PHASE III STUDY OF PATIENTS WITH ADVANCED PANCREATIC CANCER Abraxane plus gemcitabine was superior to gemcitabine alone with statistically significant and clAdd to Reading List